Notice of Intent to Sole Source – Life Technologies Corp.

Description

{"description":" The purpose of this acquisition is to purchase reagents and consumables that are needed to run Life Technologies instruments at the Department of Laboratory Medicine (DLM) at National Institutes of Health (NIH) Clinical Center (CC). \n\n \n\n \n\n • Product Service Code: 6515 – Medical Instruments, Equipment, and Supplies \n\n • NAICS Code: 339112 – Surgical and Medical Instrument Manufacturing \n\n • Place of Performance: Bethesda, MD 20892 USA \n\n \n\n POTS: 25-000661 \n\n \n\n Description: \n\n \n\n This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. \n\n \n\n The National Institutes of Health (NIH) intends to award a fixed price purchase order to Life Technologies Corporation, located at 3175 Staley Rd, Grand Island, NY 14072, on a firm fixed price sole source award basis to provide reagents and consumables that are needed to run Life Technologies instruments at the Department of Laboratory Medicine (DLM) at National Institutes of Health (NIH) Clinical Center (CC). \n\n \n\n Life Technologies Scientific is the sole-source manufacturer and supplier of the \nconsumables and kits that are used in the laboratory. There are other types of \nkits that are on the market, however, they work differently than what have been \nvalidated for our patients. These reagents have been fully validated for use in \nBCR-ABL fusion assay, cKIT mutation assay and JAK2 mutation assay. \nSwitching to another system would entail lengthy validations and would alter \ncurrent results of our protocols. The department has been very conscientious \nabout cost savings and has thoroughly investigated and validated patient testing \nusing these consumables and reagents. The possibility of inconsistent data could \nresult from switching vendors and equipment. It could also necessitate additional \nquality control mechanisms. This could cause potential delays in patient care, \nprotocols and incur unwarranted government expenditure and waste. \n\n \n\n This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. \n\n \n\n Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. \n\n \n\n Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Kristin Nagashima, Contract Specialist via email to Kristin.nagashima@nih.gov by December 17, 2025 at 12pm EST. \n"} Solicitation Number: 26-000661 Type: Special Notice Base Type: Special Notice NAICS: 339112 Classification Code: 6515 Response Deadline: 2025-12-17T12:00:00-05:00 Office Address: BETHESDA, MD Place of Performance: Bethesda, Maryland, 20892 POC: Kristin Nagashima, kristin.nagashima@nih.gov {"description":" The purpose of this acquisition is to purchase reagents and consumables that are needed to run Life Technologies instruments at the Department of Laboratory Medicine (DLM) at National Institutes of Health (NIH) Clinical Center (CC). \n\n \n\n \n\n • Product Service Code: 6515 – Medical Instruments, Equipment, and Supplies \n\n • NAICS Code: 339112 – Surgical and Medical Instrument Manufacturing \n\n • Place of Performance: Bethesda, MD 20892 USA \n\n \n\n POTS: 25-000661 \n\n \n\n Description: \n\n \n\n This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. \n\n \n\n The National Institutes of Health (NIH) intends to award a fixed price purchase order to Life Technologies Corporation, located at 3175 Staley Rd, Grand Island, NY 14072, on a firm fixed price sole source award basis to provide reagents and consumables that are needed to run Life Technologies instruments at the Department of Laboratory Medicine (DLM) at National Institutes of Health (NIH) Clinical Center (CC). \n\n \n\n Life Technologies Scientific is the sole-source manufacturer and supplier of the \nconsumables and kits that are used in the laboratory. There are other types of \nkits that are on the market, however, they work differently than what have been \nvalidated for our patients. These reagents have been fully validated for use in \nBCR-ABL fusion assay, cKIT mutation assay and JAK2 mutation assay. \nSwitching to another system would entail lengthy validations and would alter \ncurrent results of our protocols. The department has been very conscientious \nabout cost savings and has thoroughly investigated and validated patient testing \nusing these consumables and reagents. The possibility of inconsistent data could \nresult from switching vendors and equipment. It could also necessitate additional \nquality control mechanisms. This could cause potential delays in patient care, \nprotocols and incur unwarranted government expenditure and waste. \n\n \n\n This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. \n\n \n\n Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. \n\n \n\n Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Kristin Nagashima, Contract Specialist via email to Kristin.nagashima@nih.gov by December 17, 2025 at 12pm EST. \n"}